MAXCYTE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MAXCYTE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.03M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $38.63M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $41.29M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $44.26M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $33.89M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $26.17M | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | $21.62M | Mar 22, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.96M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $22.22M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $19.50M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $28.75M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $21.57M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $15.45M | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | $13.26M | Mar 22, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.80M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $31.53M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $36.55M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $39.16M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $30.25M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $23.40M | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | $19.12M | Mar 22, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.63M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($41.06M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($37.92M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($23.57M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($19.08M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($11.82M) | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | ($12.90M) | Mar 22, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($51.90M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($51.20M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($48.30M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($27.36M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($18.19M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($11.06M) | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | ($12.42M) | Mar 22, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.82M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $22.23M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $23.82M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $19.51M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $15.41M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $17.73M | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | $17.59M | Mar 22, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.41M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($27.61M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($21.69M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($14.78M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($10.68M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($8.78M) | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | ($8.80M) | Mar 22, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.77M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.65M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $3.70M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $18.48M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $3.83M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.07M | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | $1.27M | Mar 22, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.51M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $239.47M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $268.27M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $286.65M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $284.12M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $51.78M | Mar 22, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.02M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $33.22M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $36.11M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $32.69M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $21.22M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $18.55M | Mar 22, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $171.49M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $206.25M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | $232.17M | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $253.97M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $262.90M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $33.23M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $13.60M | Mar 22, 2022 |
| FY2021 | Dec 31, 2018 | $12.28M | Mar 22, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($261.48M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($216.85M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($175.80M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($137.88M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($114.30M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($95.22M) | Mar 22, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.07M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $27.88M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $46.51M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $11.07M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $47.78M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $18.76M | Mar 22, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 22, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 106.79M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 105.71M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 103.96M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 102.40M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 101.20M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 77.38M | Mar 22, 2022 |